IDEXX Laboratories (IDXX) Projected to Post Earnings on Tuesday

Key Points

• IDEXX Laboratories is set to report Q1 2026 results before the market opens on Tuesday, May 5, with analysts projecting $3.44 EPS and $1.1198 billion in revenue; the company has guided FY2026 EPS to a range of 14.290–14.800.
• In the prior quarter IDEXX beat estimates (reported $3.08 EPS vs. $2.93 expected) with revenue of $1.09 billion, up 14.3% year-over-year, and analysts forecast roughly $15 EPS for the current fiscal year and $16 for the next.
• IDXX stock recently traded around $568.22 with a market cap of $45.13 billion and a P/E of 43.48; the consensus rating is a "Moderate Buy" with a $751 target, while insiders have sold about 45,957 shares (~$29.9M) in the last 90 days.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of $3.44 per share and revenue of $1.1198 billion for the quarter. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Monday, February 2nd. The company reported $3.08 EPS for the quarter, beating the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the firm earned $2.53 EPS. The company's revenue was up 14.3% on a year-over-year basis. On average, analysts expect IDEXX Laboratories to post $15 EPS for the current fiscal year and $16 EPS for the next fiscal year.

IDEXX Laboratories Price Performance

IDXX stock traded down $6.73 during trading on Tuesday, reaching $568.22. The company's stock had a trading volume of 195,924 shares, compared to its average volume of 513,583. IDEXX Laboratories has a 1 year low of $428.09 and a 1 year high of $769.98. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $45.13 billion, a P/E ratio of 43.48, a price-to-earnings-growth ratio of 3.44 and a beta of 1.72. The company's fifty day moving average is $593.73 and its 200-day moving average is $652.77.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a "neutral" rating and a $650.00 target price for the company. BTIG Research dropped their price target on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research note on Tuesday, February 3rd. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating for the company in a report on Monday, February 9th. Weiss Ratings downgraded shares of IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, January 29th. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $751.00.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 5,371 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the completion of the transaction, the executive vice president owned 12,693 shares in the company, valued at $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the completion of the transaction, the executive vice president directly owned 19,899 shares of the company's stock, valued at $13,163,984.46. The trade was a 11.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 in the last 90 days. Company insiders own 0.79% of the company's stock.

Hedge Funds Weigh In On IDEXX Laboratories

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Compound Planning Inc. increased its position in IDEXX Laboratories by 51.9% during the fourth quarter. Compound Planning Inc. now owns 1,802 shares of the company's stock valued at $1,219,000 after acquiring an additional 616 shares during the last quarter. Invesco Ltd. raised its position in IDEXX Laboratories by 13.8% in the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company's stock worth $1,016,296,000 after purchasing an additional 181,955 shares during the period. Axxcess Wealth Management LLC raised its position in IDEXX Laboratories by 37.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 1,707 shares of the company's stock worth $1,155,000 after purchasing an additional 465 shares during the period. Birchwood Financial Partners Inc. bought a new stake in IDEXX Laboratories in the fourth quarter worth about $82,000. Finally, Corient Private Wealth LLC lifted its stake in IDEXX Laboratories by 58.9% in the fourth quarter. Corient Private Wealth LLC now owns 184,587 shares of the company's stock worth $124,879,000 after purchasing an additional 68,410 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.